PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC)

被引：0
|
作者：
Saba, N. [1 ]
Youssoufian, H. [2 ]
Cohen, E. [3 ]
Singh, J. [4 ]
Makris, L. [5 ]
Perdomini, M. [6 ]
MacIntyre, S.
Denker, A. [7 ]
机构：
[1] Emory Univ, Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA
[2] Youssoufian Hagop, Med, Boston, MA USA
[3] UC San Diego Hlth, Med Dept, Moores Canc Ctr, La Jolla, CA USA
[4] AMR Kansas City Oncol, Med Dept, Kansas City, MO USA
[5] Stathmi, Stat, New Hope, PA USA
[6] Flamingo Therapeut, Clin Dev, Illkirch Graffenstaden, France
[7] Flamingo Therapeut, Clin Dev, Philadelphia, PA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
943TiP
引用
收藏
页码：S592 / S592
页数：1
相关论文
共 50 条
  • [21] Platinum/taxane/pembrolizumab vs Platinum/5-fluorouracil/pembrolizumab in recurrent/metastatic Head and Neck Squamous Cell Carcinoma (r/m HNSCC)
    Sun, L.
    Cohen, R.
    Colevas, A. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E34 - E35
  • [22] A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.
    Cohen, Ezra E. W.
    Rischin, Danny
    Pfister, David G.
    Vermorken, Jan Baptist
    Zhao, Yufan
    Gowda, Hema
    Ge, Joy Yang
    Jin, Fan
    Harrington, Kevin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] A randomised, double-blind, placebo-controlled phase II study of setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (rmSCCHN)
    Rullan, A.
    Adkins, D. R.
    Bossi, P.
    Cohen, E. E. W.
    Daste, A.
    Harrington, K. J.
    Le Tourneau, C.
    Licitra, L. F.
    Little, N.
    Morris, T.
    Ottensmeier, C. H. H.
    Reinwald, M.
    Rutkowski, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S863 - S864
  • [24] CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001+pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Wong, Deborah J. L.
    Panwar, Aru
    Rosenberg, Ari
    Karivedu, Vidhya
    Laux, Douglas Earl
    Zandberg, Dan Paul
    Bobilev, Dmitri
    Zhao, Luping
    Wooldridge, James
    Krieg, Art M.
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study
    Adkins, Douglas
    Mehan, Paul
    Ley, Jessica
    Siegel, Marilyn J.
    Siegel, Barry A.
    Dehdashti, Farrokh
    Jiang, Xuntian
    Salama, Noha N.
    Trinkaus, Kathryn
    Oppelt, Peter
    LANCET ONCOLOGY, 2018, 19 (08): : 1082 - 1093
  • [26] An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of the interim safety analysis.
    Sacco, Assuntina Gesualda
    Messer, Karen
    Natsuhara, Amanda
    Chen, Ruifeng
    Wong, Deborah J. L.
    Worden, Francis P.
    Adkins, Douglas
    Pittman, Emily
    Zhang, Jing
    Daniels, Gregory A.
    Gold, Kathryn A.
    Espiritu, Maechelle
    Sutton, Brian
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)
    Machiels, J-P.
    Licitra, L.
    Tao, Y. G.
    Yen, C-J.
    Rischin, D.
    Waldron, J. N.
    Burtness, B. A.
    Gregoire, V.
    Agarwala, S. S.
    Yorio, J.
    Delord, J-P.
    Aksoy, S.
    Ikeda, S.
    Hong, R-L.
    Ge, J. Y.
    Brown, H.
    Bidadi, B.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2018, 29 : 398 - 398
  • [28] Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).
    Sun, Lova
    Cohen, Roger B.
    Colevas, A. Dimitrios Dimitrios
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent metastatic squamous cell carcinoma of the head and neck KEYNOTE-048): a randomised, open-label, phase 3 study (vol 394, pg 1915, 2019)
    Burtness, B.
    Harrington, K. J.
    Greil, R.
    LANCET, 2021, 397 (10291): : 2252 - 2252
  • [30] Pembrolizumab plus Olaparib vs Pembrolizumab plus Chemotherapy After Induction With Pembrolizumab plus Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study
    Rugo, Hope
    Robson, Mark
    Im, Seock-Ah
    Dalenc, Florence
    Ruiz, Eduardo Yanez
    Im, Young-Hyuck
    Kulyk, Sergii
    Dudnichenko, Oleksandr
    Llinas-Quintero, Nestor
    Saji, Shigehira
    Miyoshi, Yasuo
    Harbeck, Nadia
    Fan, Li
    Mejia, Jaime
    Karantza, Vassiliki
    Cescon, David
    CANCER RESEARCH, 2024, 84 (09)
12345